DKFZ NCT Heidelberg VomLaborInDiePraxis HARPOON 2023, focused on the latest developments in molecular precision oncology, is on its way, for the first time as a face-to-face workshop in Heidelberg.

Vielen Dank an alle, die zu diesem tollen Event beigetragen haben, vor allem die hochkarätigen Vortragenden, DKFZ, NCT Heidelberg und VomLaborInDiePraxis! Die Planungen für HARPOON 2025 haben bereits begonnen!

Excited to share our new study, published Nature Communications, in which we combined precision oncology with preclinical mechanistic research to characterize sarcomas with TFCP2 fusions. Stefan Fröhling, DKFZ, NCT Heidelberg, Hopp-Kindertumorzentrum Heidelberg (KiTZ), Universitätsklinikum Heidelberg. rdcu.be/du3YP

Please read our new precision #RareCancer medicine study, which we hope will help improve outcomes for patients with a peculiar #Sarcoma subtype that lacks effective systemic therapies. nature.com/articles/s4146…

Check @natureMedicine for a groundbreaking #GIST study. Read about #ctDNA as elegant biomarker of genomic heterogeneity. Treatment prediction 3.0! @GISTLab Robin Lewis Jones Uni Duisburg-Essen @unidue.bsky.social Uniklinikum Essen Patrick Schöffski Jon Trent, MD, PhD César Serrano García Jean-Yves Blay t.ly/htWHD

Please read this wonderful interdisciplinary work from Uniklinikum Essen and NCT Heidelberg on the use of FAPI in Solitary fibrous tumors (SFT) led by @rainerhamacher. Stefan Fröhling Jens Siveke t.ly/ylGKc

Super interesting #RareCancer study – realized through exemplary teamwork and underscoring the potential of molecularly guided radiotheranostics. Hopefully much more to come! DKFZ VomLaborInDiePraxis

Forschende DKFZ und NCT Heidelberg haben den molekulargenetischen Hintergrund eines neu entdeckten Sarkomsubtyp untersucht und Therapieansäzte abgeleitet. Rhabdomyosarkome mit TFCP2-Fusionen sind aggressive Tumoren im Kopf-Hals-Bereich, die auf herkömmliche Therapien nicht ansprechen.

Recommended 📗 of the month: "NCT/DKFZ MASTER handbook of interpreting whole genome, transcriptome, and methylome data for #PrecisionOncology"  npj Journals ➡️ rdcu.be/du2zj Vall d’Hebron Institute of Oncology (VHIO) Gustave Roussy The Netherlands Cancer Institute Karolinska Institutet CRUK Cambridge Institute DKFZ NCT Heidelberg  Istituto Tumori

Peter Horak and I had the opportunity to discuss a recent study published in Cancer Discovery that measured the coming of age of molecularly guided #PrecisionOncology. aacrjournals.org/cancerdiscover…

In the Spotlight: Measuring Progress in Precision #Oncology, by Peter Horak and Stefan Fröhling. bit.ly/48yWUu4 DKFZ NCT Heidelberg VomLaborInDiePraxis

Recently published: Claudia Scholl Stefan Fröhling Translational Medical Oncology DKFZ NCT Heidelberg Universitätsklinikum Heidelberg characterise TFCP2-rearranged #rhabdomyosarcomas using #multiomics, with insights for precision oncology #CancerResearch Cancer at Nature Portfolio nature.com/articles/s4146…

In diesem The German Human Genome-Phenome Archive-Podcast erklären Dr. Gräßner U.n.i Klinik TTDI und Prof. Stefan Fröhling NCT Heidelberg, DKFZ und Universitätsklinikum Heidelberg wie genetisches Wissen die Medizin und Versorgung optimiert, wodurch #SelteneErkrankungen und #Krebs besser behandelt werden können. codedeslebens.podigee.io/5-genetikwisse…

#DKFZ/#NCT/#DKTK-MASTER beim #DKK2024: Dr. Simon Kreutzfeldt sprach über das MASTER-Programm und die große Chance präzisionsonkologischer Ansätze im Bereich der seltenen #Tumorerkrankungen für den individuellen Patienten und für die Wissenschaft.

CCE Rare Tumors TF, led by Stefan Fröhling César Serrano García, aims to combine forces to increase the understanding of #rarecancers, and encourage communication and collaboration among + 40 researchers and clinicians from #CCE centres. #RareDiseaseDay ➡️ rb.gy/ju19s9

Seltene Krebserkrankungen wie #Sarkome müssen noch besser erforscht werden. Forschende des DKFZ und NCT Heidelberg klären dank spezieller Programme immer mehr Details über sie auf – die Basis neuer #Therpieansätze: bit.ly/42Zeu8D Stefan Fröhling #RareDiseaseDay #XgegenKrebs

Heute ist Tag der Tag der seltenen Erkrankungen - zu denen auch #Sarkome gehören. Über neue Ansätze von Forschenden des @dkfz und des @nct_hd zur zielgerichteten Behandlung von Sarkomen berichtet die #XgegenKrebs:

Happy to share our new study, published Nature Communications, in which we used single-cell transcriptomics of enriched rare and actively dividing lung cells to examine how lung cells respond to targeted damage. DKFZ, NCT Heidelberg. Paper 👉 rdcu.be/dA1ii Briefly, …

📢Register now for today's (13/3) 3rd webinar in our #PrecisionOncology series. This virtual discussion will analyse the complexities involved in establishing and managing molecular tumour boards. ow.ly/53HV50QS87V Ben Westphalen Åslaug Helland Stefan Fröhling Bettina Ryll

Do you want to do excellent #postdoc research supported by one of the most prestigious fellowships in 🇪🇺? Do you want to work at a leading institution with world-class scientists from all over the world? Then apply to the DKFZ #MarieCurie MasterClasses via t1p.de/l01hq